



## Labomar attends “ISMO - Italian Stock Market Opportunities” in Paris on July 1

Istrana (TV), June 27, 2022 — Labomar SpA (Euronext Growth Milan, Ticker: LBM), an Italian-based international nutraceutical enterprise and listed on the Euronext Growth Milan market, is attending the “ISMO - Italian Stock Market Opportunities”, event organized by Intesa Sanpaolo, that will be held in presence on July 1 in Paris, at the “Hôtel Ritz”, Place Vendôme.

On this occasion, Labomar’s management team composed by **Walter Bertin, Chief Executive Officer, Claudio De Nadai, Board Member and IR Manager, Claudio Crespan, CFO, and Francesco Da Riva, Head of Sales** will share with the financial community the latest company news and strategies’ update.

Materials dedicated to investors are available on the Company’s website [www.labomar.com](http://www.labomar.com), “Investors” section.

### Labomar Profile

Founded by Walter Bertin in Istrana (province of Treviso) in 1998, Labomar is specialised in the development and production of food supplements, medical devices, foods for special medical purposes and cosmetics for third parties. Over more than 20 years, Labomar has built a business model which sets it apart from its competitors and generates value for all stakeholders, providing a comprehensive service and a high quality and productivity standard. The company boasts a well structured and cutting-edge research and development department with a particular focus on innovation, a commercial team which reacts quickly to market demands and a high level of product differentiation thanks to its proprietary patents and formulas.

Labomar reported in 2021 consolidated revenues of approx. Euro 65.4 million, up 7.1% on 2020. The 2021 figure includes, in addition to the revenues of the parent company and the Canadian Entreprises ImportFab Inc., also those for H2 of the Welcare Group and, for December alone, of Labiotre Srl. Labomar SpA’s revenues in 2021 were approx. Euro 53.8 million, increasing nearly 4 percentage points on 2020.

Labomar in 2021 acquired 70% of the Welcare Group. The Group comprises Welcare Industries Spa and Welcare Research Srl, producers of medical devices for skincare, with its registered office in Orvieto. LaboVar Srl was also established - 51% owned by Labomar - for the sale of nutraceutical products on an e-commerce platform on the Chinese market. Labomar then acquired full control of Labiotre Srl, a Tuscan enterprise specialising in the production of plant extracts, fully integrating the supply chain concept advocated by the company.

Labomar sincerely believes in operating as a business centred on sustainability and the well-being of the individual, the environment and the community. It has therefore amended its By-Laws to become a Benefit company. This new legal status, introduced in Italy in 2016, formalises the decision to develop a responsible, sustainable and transparent development model, which marries operating-earnings objectives with social and environmental aspects.



***For further information:***

***Labomar Press Office***

Thanai Bernardini - +39.335.7245418 - [me@thanai.it](mailto:me@thanai.it)

Alessandro Bozzi Valenti - +39.348.0090866 - [alessandro.valenti@thanai.it](mailto:alessandro.valenti@thanai.it)

***Investor Relations Labomar***

Claudio De Nadai - +39.0422.677203 - [claudio.denadai@labomar.com](mailto:claudio.denadai@labomar.com)

Mara Di Giorgio - +39 335 7737417 - [mara@twin.services](mailto:mara@twin.services)

***Euronext Growth Advisor***

Banca Mediolanum - +39 02 9049 2525 - [ecm@mediolanum.it](mailto:ecm@mediolanum.it)